Pharmacokinetic Similarity and Comparative Pharmacodynamics, Safety, Efficacy, and Immunogenicity of DRL_RI Versus Reference Rituximab in Biologics-Na ïve Patients with Moderate-to-Severe Rheumatoid Arthritis: A Double-Blind, Randomized, Three-Arm Study

ConclusionDRL_RI, a proposed biosimilar, demonstrated three-way PK similarity with RTX-EU and RTX-US, the reference innovator products, with comparable efficacy, PD, safety, and immunogenicity.Clinical Trials Registration NumberClinicalTrials.gov identifier: NCT02296775.

http://link.springer.com/10.1007/s40259-020-00406-1

Source: BioDrugs - February 11, 2020 Category: Drugs & Pharmacology Source Type: research